title
stringlengths
1
1.19k
keywords
stringlengths
0
668
concept
stringlengths
0
909
paragraph
stringlengths
0
61.8k
PMID
stringlengths
10
11
Methods
150 patients, ASA physical status I–II, aged ≥ 60 years, no limitation in gender, BMI 18–25 kg/cm
PMC10069053
Results
There was no significant difference in VAS score and PCA compression times (
PMC10069053
Conclusions
depression, postoperative pain, anxiety
Esketamine can reduce short-term postoperative anxiety and depression, relieve postoperative pain and stress response, shorten bed rest time after total hip replacement, and accelerate postoperative recovery.
PMC10069053
Keywords
PMC10069053
Introduction
fractures, Femoral neck fractures
Femoral neck fractures account for roughly 54% of hip fractures [
PMC10069053
Materials and methods
PMC10069053
Clinical data
depression, femoral neck fracture, THA
Since there is no accurate result of esketamine in reducing the depression rate after THA in patients with femoral neck fracture, the main measure was defined as the depression rate 7 days after surgery, assuming that the difference between the two groups was up to 20%. According to a unilateral test conducted using th...
PMC10069053
Methods
pain
All patients were fasting and drinking water before operation. After entering the operating room, ECG, SBP, DBP, SPO2 and BIS were monitored. Conventional open venous access was used for intravenous infusion of compound sodium chloride injection, low flow nasal oxygen inhalation (2L/min), radial artery puncture and cat...
PMC10069053
Observational indices
dizziness, nausea, postoperative adverse reactions, HAD
CHRONIC ILLNESS
Patients' demographic information was gathered, including age, gender, BMI, level of education, occupation, chronic illness, preoperative HAD and preoperative Harris scores, length of surgery, and length of hospital stay. The first time out of bed, the ambulation distance, and the number of PCA presses within 48 h afte...
PMC10069053
Statistical analysis
SPSS26.0 software was adopted for data analysis, measurement data are represented as
PMC10069053
Results
PMC10069053
General data
There was no significant difference in baseline characteristics between the two groups (Comparison of general data between the two groups
PMC10069053
Postoperative VAS score
There was no significant difference in VAS scores between the two groups at rest and in active state after operation (Comparison of postoperative VAS scores between the two groups (points, M(IQR))
PMC10069053
Patient recovery, length of hospital time and PCA compression times
The time of first getting out of bed, the distance of activity and the length of hospital stay in group A were better than those in group B, and the differences were statistically significant (The first time to get out of bed, the distance of activity and the length of hospital stay were compared between the two groups...
PMC10069053
Comparison of adverse responses between the two groups
dizziness, postoperative adverse reactions, nausea, vomiting
Compared with group A, the incidences of nausea, vomiting and dizziness in group B were significantly higher (Comparison of postoperative adverse reactions between the two groups [
PMC10069053
Patient stress index
There was no significant difference in the levels of IL-6 and CRP between the two groups in the morning of the operation day (Comparison of IL-6 and CRP between the two groups.
PMC10069053
Comparison of patients’ HAD scores
depression, HAD, anxiety
Compared with group B, the scores of anxiety and depression in group A were significantly reduced at 3 days and 1 week after operation, and the differences were statistically significant (HAD scores were compared between the two groups.
PMC10069053
Harris score
The Harris score of group A at 3 days, 1 week and 1 month after operation was significantly higher than that of group B, and the difference was statistically significant (Harris score was compared between the two groups at 3 days, 1 week and 1 month after operation (
PMC10069053
Discussion
femoral neck fractures, anxiety, nausea and vomiting, pain, dizziness, depression, trauma
ADVERSE EFFECTS, SCHWARTZ
The most common form of depression in older patients with femoral neck fractures is anxiety [The results of this study showed that there was no significant difference in VAS score between the two groups within 48 h after operation, but in terms of adverse effects, esketamine group in the incidence of nausea and vomitin...
PMC10069053
Conclusions
depression, anxiety, pain
Esketamine has good clinical application value because it can more effectively relieve pain in elderly patients who have had total hip arthroplasty, reduce perioperative stress response, improve perioperative anxiety and depression symptoms, shorten bed rest time, and encourage postoperative rehabilitation.
PMC10069053
Author contributions
MM
MM was responsible for the design, implementation and manuscript writing. DC was responsible for literature search and follow-up. CX is responsible for data processing and literature search. XW is in charge of manuscript editing. All authors have contributed to the manuscript and all authors have approved the submissio...
PMC10069053
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
PMC10069053
Declarations
PMC10069053
Competing interests
The authors declare no competing interests.
PMC10069053
References
PMC10069053
Background
orthodontic
Whether slim the face or not after removed third molars is the concern of some orthodontic treatment candidates. The aim of this article is to explore the volume changes of facial soft and hard tissues after third molars extraction, as well as develop a reproducible clinical protocol to precisely assess facial soft tis...
PMC10362706
Methods
A non-randomized, non-blind, self-controlled pilot study was conducted. 24 adults aged 18–30 had ipsilateral third molars extracted. The body weight change was controlled within 2 kg. Structured light scans were taken under a standardized procedure pre-extraction (T0), three (T1), and six (T2) months post-extraction; C...
PMC10362706
Results
The final sample size is 23, including 5 males (age 26.6 ± 2.5 years) and 18 females (age 27.3 ± 2.5 years). The HTVC was − 2.33 ± 0.46ml on the extraction side. On the extraction side, the STV decreased by 1.396 (95% CI: 0.323–2.470) ml (P < 0.05) at T1, and increased by 1.753 (95% CI: -0.01-3.507) ml (P = 0.05) at T2...
PMC10362706
Conclusions
After ipsilateral wisdom teeth extraction, the volume of hard tissue on the extraction side reduces, and the volume of facial soft tissue does not change evidently. However, further research with large sample size is still needed. The STV measurement has excellent repeatability. It can be extended to other interested a...
PMC10362706
Trial registration
ChiCTR, ChiCTR1800018305 (11/09/2018),
PMC10362706
Keywords
PMC10362706
Background
tooth, atrophies
SLS, ATROPHIES
The wisdom teeth extraction influences maxillofacial hard tissue dimensions and may affect facial soft tissue dimensions. Previous research proved that the alveolar bone is tooth-dependent tissue and atrophies due to the loss of the tooth [Presume “face slim” happens, the soft tissue change is relatively small which ne...
PMC10362706
Methods
PMC10362706
Study design/sample
inflammation, periodontitis, pericoronitis, tooth
INFLAMMATION, PERIODONTITIS, PERICORONITIS, IMPACTION
A non-randomized, non-blind, self-controlled clinical study was conducted.Sample size calculation: According to the method by W. Viechtbauer et al. [Inclusion criteria: 18–30 years old, with a balanced face; Voluntary to pull out ipsilateral wisdom teeth simultaneously. There is no limit of the impaction classification...
PMC10362706
Clinical intervention and follow-up
SLS
The ipsilateral third molars were extracted by the same experienced surgeon at one follow-up visit. SLS and the bodyweight were taken at T0, T1, and T2. CBCT was taken at T0 and T2. Patients were required to control weight change within ± 2 kg.
PMC10362706
The data collection
PMC10362706
SLS acquisition
SLS
The parameters of the FaceScan SLS system (Isravision, Darmstadt, Germany) are: scanning speed of 0.8 s, scanning accuracy of 0.2 mm, scanning range from 270 degrees to 320 degrees, 5 million CCD pixels. A standardized procedure [
PMC10362706
CBCT acquisition
teeth bite
CBCT images were taken with i-CAT (Imaging Sciences International, Hatfield, PA, USA) at 120kVp, 18.45mAs, 20-second acquisition time, and 16 × 13 cm field of view. The effective radiation dose was 69–87µSv. Each patient was instructed to hold still, maintain her or his head upright and fixed by a headrest, with the te...
PMC10362706
The data evaluation
PMC10362706
SLS analysis
SD
The facial scans were processed in Geomagic 2014 (2014, Germany) software by the following steps: Alignment and registration:The scan of T0 was set to be a fixed module, while the scans of T1 and T2 were floating modules. T1 and T2 scans were registered to T0 according to the upper third of the face [ The registration ...
PMC10362706
CBCT analysis
The CBCTs were imported into Dragonfly software (version 4.3, Objects Research Systems, Montreal, QC, Canada) in DICOM format for analysis. Alignment based on voxel information.CBCT of T0 was set as a “fixed module”. CBCT of T2 was aligned to the T0 through manual rotation and translation until the teeth and bone conto...
PMC10362706
Statistical methods
Data were analyzed using SPSS software (version 23.0; SPSS, IBM; Chicago). As for the reliability of the projection method, the intraclass correlation coefficient (ICC) for absolute agreement, single measure, based on 2-way random effects, was calculated. The Shapiro-Wilk test was used to assess the data distribution. ...
PMC10362706
Results
A total of 24 volunteers were recruited, and one (male, age 30) was excluded due to unqualified data. Specifically, there was obvious deformation in the post-extraction facial scan, which may be due to the mandible position deviation or the defect of structural light scanning. A total of 23 volunteers were included, in...
PMC10362706
Discussion
SLS, IMPACTION
The pilot study is exploratory in methodological feasibility of facial soft tissue volume measurement and rationality of experimental design for the preparation of further research. A non-randomized, non-blind, and self-controlled clinical trial was conducted to measure the 3D soft and hard tissue changes of the human ...
PMC10362706
Acknowledgements
The author would like to thank the National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, PR China, for software support.
PMC10362706
Authors’ contributions
SLS
WXW designed and operated the study, and write the manuscript. YHH processed the CBCT data. WEB extracted teeth and collected clinical data. CXY processed part of the SLS data and duplicated the STV measurement. ZYJ contributed to the software utilization. JJH designed the study and revised the manuscript. All authors ...
PMC10362706
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
PMC10362706
Data Availability
All data generated or analysed during this study are included in this published article.
PMC10362706
Declarations
PMC10362706
Competing interests
The authors declare that they have no competing interests.
PMC10362706
Ethics approval and consent to participate
This study was approved by the ethics committee of Peking University School of Stomatology, Beijing, China (number PKUSSIRB-201838117). Informed consent has been obtained from all volunteers in written. All methods in this study were carried out in accordance with relevant guidelines and regulations.
PMC10362706
Consent for publication
Informed consent for publication of images has been obtained from the volunteer.
PMC10362706
List of abbreviations
soft tissue volumehard tissue volumesoft tissue volume changehard tissue volume changeStructured light scanningCone-beam computed tomographyRoot mean squareRegions of interestIntraclass correlation coefficientIterative closest point
PMC10362706
References
PMC10362706
ABSTRACT
PMC10375926
Background
muscle soreness, fatigue
Olive fruit is rich in bioactive pentacyclic triterpenoids, primarily maslinic acid (MA). Previous studies have demonstrated that MA exhibits anti-inflammatory and anti-oxidative effects; however, it is unclear whether MA intake during training inhibits perceptual fatigue and muscle soreness in athletes. This study ana...
PMC10375926
Methods
muscle soreness, perceptual fatigue
This randomized, double-blind, cross-over, and placebo-controlled trial involved 12 young, healthy male water polo athletes. After daily training for seven days, they ingested either olive fruit extract, containing 60 mg/day MA, or a placebo. We measured perceptual fatigue and muscle soreness during the intervention us...
PMC10375926
Results
Perceptual fatigue, muscle soreness
Perceptual fatigue and muscle soreness and the area under the curve during the training period were significantly lower (main effect of MA;
PMC10375926
Conclusion
inflammation, muscle soreness, perceptual fatigue
INFLAMMATION, OXIDATIVE STRESS
These findings suggest that MA intake not only reduces perceptual fatigue and muscle soreness but also decreases inflammation and oxidative stress in the blood and skeletal muscle.
PMC10375926
GRAPHICAL ABSTRACT
PMC10375926
KEYWORDS
PMC10375926
Introduction
fatigue
INFLAMMATION, GLYCOGEN DEPLETION
Chronic fatigue can impact physical and mental athletic performance. A tired athlete may have less energy to exert themselves during practice or a game. Exercise-induced fatigue, which is attributable to many factors, including the accumulation of reactive oxygen species, inflammation, and muscle glycogen depletion, af...
PMC10375926
Materials and methods
PMC10375926
Participants
This randomized, placebo-controlled, double-blind trial was conducted with 12 Japanese first-division national-level male university water polo athletes. The characteristics of the participants are shown in Grouping condition and characteristics of participants.Training schedule from Day 1 to Day 7 during intervention.
PMC10375926
Training schedule
The participants maintained a fixed training regimen (
PMC10375926
Anthropometric measurements
Anthropometric measurements were performed bare feet in light clothes. Body mass was measured to the nearest 0.1 kg using a digital scale (InBody 770; InBody Japan, Tokyo, Japan). Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer (Digital Height Meter AD-6227 by A&D, Tokyo, Japan). Body mass in...
PMC10375926
Performance trial (eggbeater kick ability)
Participants conducted the performance trial measurements in a 50-m indoor pool with a maximum depth of 3.8 m. A blood sample was taken from the fingertip and blood lactate levels were measured with Lactate Pro2 (Arkray. Kyoto. Japan) before and after the performance trial. Participants performed a 20-second eggbeater ...
PMC10375926
Perceptual assessments of fatigue and muscle soreness
muscle soreness, fatigue
The perceptual assessment of fatigue and muscle soreness in the whole or parts of body were surveyed using the visual analog scale (VAS) [
PMC10375926
Serum tumor necrosis factor α (TNF-α) levels and other biochemical markers
TNF-α
BLOOD
Blood samples were collected from each participant in the morning after fasting for 12 h overnight. Each blood sample was placed in a serum separator tube and centrifuged at 2,000 rpm for 15 minutes at 4°C. The serum was stored at −80°C until further analysis. Serum TNF-α levels were measured by ELISA using the Human T...
PMC10375926
Thiobarbituric acid reactive substance (TBARS) assay
Serum TBARS were measured as described previously [
PMC10375926
Cell culture
WEST
Murine C2C12 skeletal muscle cells (passage numbers 10–12) were seeded into 12-well plates and maintained in Dulbecco’s modified Eagle’s medium (DMEM) (11966025, Gibco) containing 10% (vol/vol) fetal bovine serum (FBS; F9665, Sigma-Aldrich, St. Louis, MO), 1% (vol/vol) penicillin-streptomycin (15070–063, Gibco), 5 mM g...
PMC10375926
Western blot analysis
LYSIS
Total protein from the C2C12 cells was extracted with a lysis buffer containing 50 mM HEPES (pH: 7.6), 150 mM NaCl, 10 mM EDTA, 10 mM Na
PMC10375926
Primary antibodies
TNF-α
The following primary antibodies were used for western blot analysis: TNF-α (1:500, 52B83; sc -52,746, Santa Cruz), total-nuclear factor-kappa B (NF-κB) (1:1000, #8242; Cell signaling Technology, Danvers, MA, USA), phospho-NF-κB (1:1000, #3033; Cell signaling Technology, Danvers, MA, USA), cyclooxygenase 2 (COX2) (1:10...
PMC10375926
Statistical analyses
Data are expressed as means ± standard deviation (SD) or individual values (
PMC10375926
Results
PMC10375926
P
To determine whether MA affects treading water performance, we measured the maximum number of sets of high-intensity interval exercises with an eggbeater kick for water polo athletes. The exhaustion set count for the performance trial was lower than before the intervention but was not affected by MA intake (data are no...
PMC10375926
Perceptual fatigue and muscle soreness
fatigue, muscle soreness, lower back muscle soreness, femur muscle soreness, muscle fatigue, chest muscle soreness, perceptual fatigue
We measured perceptual fatigue and muscle soreness as the primary outcomes. Regarding fatigue, whole-body fatigue and muscle fatigue were lower in the MA condition compared with those in the placebo condition (MA intake attenuates perceptual fatigue and muscle soreness during the one-week intervention. (a) whole body f...
PMC10375926
Inflammatory and damage markers in blood
inflammation, TNF-α
INFLAMMATION
To elucidate the mechanism of the anti-inflammatory effects of MA, we measured inflammatory (TNF-α and high sensitive C-reactive protein) and damage (CK and creatinine) biomarkers in the blood. For TNF-α, an interaction was observed between the placebo and the MA condition after intervention and the rate of change in T...
PMC10375926
Oxidative stress (TBARS) in blood
OXIDATIVE STRESS
To determine the effect of MA on oxidative stress, we measured TBARS in the serum. TBARS is a representative oxidative stress marker and is a protein that is primarily produced when fat is oxidized. Between the placebo and MA conditions after the intervention, an interaction was observed (interaction: MA intake inhibit...
PMC10375926
Inflammatory and antioxidant related proteins in vitro
Finally, we performed an Inflammatory related proteins are decreased within myotubes treated with serum from MA-conditioned participants after intervention. (a) western blot band images, protein expression levels of (b) TNF-α, (c) NF-κB, and (d) COX2. All data are expressed as means and individual values (Antioxidant f...
PMC10375926
Discussion
INFLAMMATION, OXIDATIVE STRESS
The findings of this study show that seven consecutive days of MA supplementation effectively reduced perceptual fatigue, soreness, inflammation, and oxidative stress markers in the blood in highly trained water polo athletes. In an
PMC10375926
MA and exercise performance
muscle soreness, muscle damage, fatigue
INFLAMMATION, OXIDATIVE STRESS
This is the first study to report the effects of MA supplementation on inflammation, oxidative stress, and swimming (treading water) performance in team sport athletes. Contrary to our (and previous studies) hypothesis, the MA ingestion did not affect performance, but suppressed perceptual fatigue and muscle soreness. ...
PMC10375926
Perceptual evaluation
arthralgia pain
HAND ARTHRITIS
We observed the main effect of MA in all indexes of the evaluation by VAS, which is the main outcome of this study. Our previous study reported that MA attenuates arthralgia pain in the elderly and arthritis in inflammatory mouse models [
PMC10375926
Evaluation of inflammatory and oxidative stress in blood
INFLAMMATION, OXIDATIVE STRESS
We quantified some factors associated with inflammation, damage, and oxidative stress in the blood plasma to determine the effects of MA intake. Reduced inflammation, damage, and oxidative stress after intervention indicate the maintenance of muscular function. It likely mitigates soreness, possibly explaining the pres...
PMC10375926
Effects of MA-ingested serum on cultured cells
inflammation
INFLAMMATION, OXIDATIVE STRESS
As a new insight, we investigated whether the addition of serum before and after the intervention from the participants to cultured cells would affect the protein expression on inflammation or antioxidant. This experiment enables us to examine in more detail the effects of MA and metabolites resulting from MA intake. A...
PMC10375926
Limitations
inflammation
INFLAMMATION
One limitation of this study was the short duration of MA ingestion. Our study was conducted for a short period of one week to ascertain the impact of MA on inflammation and injury. In addition, because this study was conducted with active athletes, it was limited to one week because of the constraints of accommodating...
PMC10375926
Conclusion
inflammation, muscle soreness, fatigue
INFLAMMATION, OXIDATIVE STRESS
In this study, we determined the effect of MA on fatigue and muscle soreness in a randomized, double-blind, cross-over, and placebo-controlled trial. Our results suggest that MA intake for one-week significantly attenuated fatigue and muscle soreness by reducing inflammation and damage. Furthermore, we found novel MA b...
PMC10375926
Abbreviations
Tumor necrosis
TUMOR NECROSIS
ANOVA: analysis of variance, AUC: area under the curve, BMI: Body mass index, CK: Creatine kinase, COX2: Cyclooxygenase 2, DMEM: Dulbecco’s modified Eagle’s medium, GPX: Glutathione peroxidase, Hmox1: Heme oxygenase 1, hs-CRP: High-sensitivity C-reactive protein, MA: maslinic acid, mTOR: Mechanistic target of rapamycin...
PMC10375926
Acknowledgments
Ota
The authors would also like to thank Kohei Takeda (Meiji University), Yuya Ota, Hideto Hanakita, Shota Kumamoto, Koichiro Tanahashi, and Jiyeon Park (University of Tsukuba) for help with the measurements.
PMC10375926
Disclosure statement
This study was funded by NIPPN CORPORATION. Yuki Yamauchi and Keito Suzuki are employees of NIPPN CORPORATION. The other authors have no personal or financial conflicts of interest.
PMC10375926
Author contributions
Significant manuscript writer: TS. Concept and design: T.S., E.K., K.M., Y.Y., K.S., and T.T. Data acquisition: T.S., E.K., K.M., Y.Y., and K.S. Data analysis and interpreted: T.S. and YY. Prepared figure: T.S. Drafted manuscript: T.S. Edited and revised manuscript: T.S., H.T., S.M and T.T. All authors read and approve...
PMC10375926
Data availability statement
The sharing of data in an open-access repository was not included in our participants consent. Thus, in accordance with standard ethical practice, data may only be available on request from the corresponding author.
PMC10375926
Ethics approval
This study conformed to the Declaration of Helsinki principles and was approved by the University of Tsukuba Research Ethics Committee approved this study (Tai29–75). This study was registered in the UMIN Clinical Trial Registry under the ID UMIN 000030479. Written informed consent was obtained from all participants be...
PMC10375926
Consent for publication
The Journal of the International Society of Sports Nutrition submission standards and the article’s content have the approval of all authors.
PMC10375926
References
PMC10375926
Background
bleeding, non-critically ill
BLEEDING
Randomized clinical trials in non-critically ill COVID-19 patients showed that therapeutic-dose heparin increased survival with reduced organ support as compared with usual-care thromboprophylaxis, albeit with increased bleeding risk. The purpose of the study is to assess the safety of intermediate dose enoxaparin in h...
PMC10594805
Methods
bleeding
DISEASE, BLEEDING
A phase II single-arm interventional prospective study including patients receiving intermediate dose enoxaparin once daily according to body weight: 60 mg for 45–60 kg, 80 mg for 61–100 kg or 100 mg for > 100 kg for 14 days, with dose adjustment according to anti-factor Xa activity (target range: 0.4–0.6 UI/ml); an ob...
PMC10594805
Results
bleeding
BLEEDING, EVENT
Major bleeding was similar in IC (1/98 1.02%) and in the OC (none), with only one event observed in a patient receiving concomitantly anti-platelet therapy. The composite outcome was observed in 53/98 patients (54%) in the IC and 132/203 (65%) patients in the OC (
PMC10594805
Conclusions
non-critically ill
Weight adjusted intermediate dose heparin with anti-FXa monitoring is safe with potential positive impact on clinical course in COVID-19 non-critically ill patients.
PMC10594805
Trial registration
The study INHIXACOVID19 was registred on ClinicalTrials.gov with the trial registration number (TRN) NCT04427098 on 11/06/2020.
PMC10594805